Key terms
About FBIO
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FBIO news
Apr 09
6:17am ET
Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments
Mar 28
4:22pm ET
Fortress Biotech reports FY23 EPS ($8.47) vs. ($15.97) last year
Mar 19
7:03am ET
Fortress Biotech initiated with a Buy at Alliance Global Partners
Mar 15
4:58am ET
Fortress Biotech resumed with a Buy at Roth MKM
Mar 04
8:40am ET
Fortress Biotech, Cyprium Therapeutics announces $4.1M grant from NINDS
Jan 27
4:18am ET
Fortress Biotech Announces Eric Rowinsky’s Board Departure
No recent press releases are available for FBIO
FBIO Financials
Key terms
Ad Feedback
FBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
